In a report released today, Alethia Young from Credit Suisse maintained a Buy rating on Acceleron Pharma (NASDAQ: XLRN), with a price target of $55. The company’s shares opened today at $36.24.
According to TipRanks.com, Young is a 2-star analyst with an average return of 0.9% and a 44.2% success rate. Young covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Sarepta Therapeutics, and Coherus Biosciences.
Currently, the analyst consensus on Acceleron Pharma is Moderate Buy and the average price target is $55.50, representing a 53.1% upside.
In a report issued on April 26, H.C. Wainwright also maintained a Buy rating on the stock with a $62 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $46.93 and a one-year low of $24.37. Currently, Acceleron Pharma has an average volume of 297.2K.
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is neutral on the stock. Most recently, in March 2018, Tom Maniatis, a Director at XLRN bought 18,750 shares for a total of $95,250.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maneates in June 2003 and is headquartered in Cambridge, MA.
